Private Equity

AM Best affirms Fairfax's 'Excellent' rating after a year of record profits and major catastrophes. We deconstruct the strategy behind this financial paradox.

In nine years, Wellington-Altus hit $50B AUA and a 7th top-dealer award. It's more than growth; it’s a strategic coup for advisor independence.

BBH's hire of Darrell Holley isn't just a personnel move; it's a calculated bet on relationship-driven advisory for private energy firms navigating a complex future.

Titans of finance, tech, and policy will converge at the CAIS Summit to navigate AI's impact and geopolitical shifts on the future of alternative investments.

With the hire of veteran Dr. Jesko Kornemann, advisory firm Cork Gully makes a strategic push into Frankfurt, betting on a growing need for special situations expertise.

MIT's Kristin Forbes argues rigid models are failing. She's adapting Sun Tzu's 'Art of War' to help central banks fight today's lightning-fast crises.

As Senator Bernie Sanders prepares to address AI's future, his proposals signal a radical new front in his war on inequality—one that could reshape the midterms.

With a major investment from PSG, Dockwa is using AI to transform the $57B marina economy, turning fragmented businesses into a new institutional asset class.

Amid global uncertainty, Deerpath Capital's $452M CLO reset offers a masterclass in financial strategy, prioritizing stability for long-term investors.

Innesto Partners' acquisition of German specialist Hausmann Aero isn't just a deal; it's a strategic play using the search fund model to bolster Europe's defense autonomy.

Consuelo Vanderbilt Costin's recurring role at the elite Forbes Iconoclast Summit is no social engagement. It's a masterclass in converting legacy into currency.

A new partnership aims to scale AI-generated software. We analyze the tech, security, and market impact of this move to redefine enterprise development.

Australian firm Taurus Management Group is opening the exclusive world of IPOs to independent investors, but does "democratization" come with a catch?

A recent FDA approval for a generic cancer drug adds to a growing market, revealing the strategic alliances redefining healthcare access.

Fresh off its IPO, Bill Ackman's firm is ditching the exclusive call for open X Spaces Q&As. A signal of radical transparency or a new compliance risk?

As corporate interests reshape medicine, a leading physician's call for stewardship revives a debate on the soul of healthcare. Can timeless values survive?

Ontra elevates its first finance hire, Andy Lujan, to CFO. A look at how his nine-year journey and military discipline will steer the AI leader's next chapter.

A call for research on vaccine side effects exposes a deeper crisis: the collapse of public trust in science. Can rigorous data heal a polarized nation?

Bluejay Diagnostics secures critical funding to advance its rapid sepsis test, extending its cash runway but raising questions about shareholder dilution.

Stonegate Capital's updated coverage validates AB Science's pivot to ALS and AML, but can its promising clinical assets and shrewd financing de-risk the path forward?